3D Cell Culture Market To Hit Value $3.31 Billion By 2030 |Grand View Research, Inc.

Author : Mrudula Karmarkar | Published On : 18 Jan 2024

San Francisco, 18 January 2024: The Report 3D Cell Culture Market Size, Share & Trends Analysis Report By Technology (Scaffold Based, Scaffold Free), By Application (Cancer, Drug Development), By End-use, By Region, And Segment Forecasts, 2023 - 2030

The global 3D cell culture market size is expected to reach USD 3.31 billion by 2030, expanding at 11.04% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is driven by technological advancements in in-vitro testing models, a rising focus on personalized medicine, and supportive government legislation for R&D. Moreover, the increasing prevalence of chronic disorders, and the growing significance of cell therapies in their treatment have created momentum for industry expansion.

Tissue engineering has made significant developments in creating 3D culture models that mimic the in-vivo culture media more precisely than the conventional 2D cell cultures. This resulted in increased utilization of 3D cell culture systems for toxicity testing, drug discovery, and regenerative medicine development. Also, recent product launches from industry players have supported market growth to a significant extent. For instance, in August 2021, Amerigo Scientific launched its 3D cell culture products for research purposes with wide applications in medicine, drug discovery, and tissue engineering.

In addition, the development of advanced technologies like microfluidics, bioprinting, and high-content screening systems, has leveraged the capabilities of these models. These technologies allow excellent control over culture conditions, cell organization, and the capability to perform high-efficiency screening, thereby fueling the utilization of 3D culture systems. Moreover, increased collaboration between market players to utilize bioprinting and microfluidics techniques in developing culture models has propelled market growth. For instance, in June 2020, CELLINK and Lonza collaborated to offer 3D bioprinting solutions to optimize access to 3-dimensional cell cultures workflows.

3D cultures can closely replicate the typical microarchitecture and morphology of organs and hence are continuously developed for studies that require in vivo models to analyze the effect of a drug over body tissues and organs. This factor, coupled with the availability of several choices in terms of the material and structure of the scaffold for a variety of in-vitro applications, is anticipated to boost revenue generation for scaffolds.

Recent research has explored the use of a broad range of scaffolds, such as graphene scaffolds, nanofibers, natural marine collagen, freeze-casting, and others. In addition, emerging applications of techniques such as lab-on-a-chip in several assay types, including proliferation, stimulation, viability, transport, high content screening, patch clamping, and metabolic activity are anticipated to lead to an increase in demand for advanced and efficient solutions.

Request sample report of 3D Cell Culture Market@ https://www.grandviewresearch.com/industry-analysis/3d-cell-culture-market/request/rs1

The growth of the market can be attributed to the rising efforts to develop potential alternatives to animal-based testing and the availability of funding programs for research. Moreover, consistent efforts in R&D activities by biopharmaceutical companies for drug development & discovery, and emphasis on the adoption of 3D cell cultures in cancer research are other factors anticipated to fuel market growth over the projected period. Animal models are largely used in cellular-based studies for studying the outlook of various diseases. However, they carry several demerits such as a lack of response accuracy, differences in response from different species, etc. Thus, to manage these issues, various government organizations are involved in promoting alternative ways for drug development.

3D Cell Culture Market Report Highlights

• The scaffold-based technology segment dominated the market in 2022 with a revenue share of 48.85% and is attributed to the increasing application of scaffold-based cultures in tissue engineering and regenerative medicine applications
• Stem cell research & tissue engineering held the largest share of 33.76% in 2022, whereas the cancer institute segment is expected to witness the fastest growth owing to the rising prevalence of cancer, and the benefits offered by 3D cell cultures in cancer research
• In the end-use segment, biotechnology and pharmaceutical companies dominated the market with a revenue share of 46.34%. The higher revenue growth is attributed to the continuous growth and commercial success of biopharmaceuticals coupled with the expanding portfolio of the major pharmaceutical companies
• North America region dominated the global market in 2022 with a revenue share of 45.58%, owing to the presence of advanced healthcare infrastructure, developed economies, the presence of key players, and various strategic initiatives undertaken by them

For instance, the REACH Act, The directive on the protection of animals used for scientific purposes, and CLP are a few of the EU regulations that strongly promote alternative ways of animal testing.

The rising burden of chronic diseases, and medical ailments such as multiple organ failure has created a robust demand for organ transplants. Whereas the dearth of donors has propelled the demand for alternative solutions, like regenerative medicine and tissue engineering. The 3D cell cultures system has an important role in nurturing organoids and functional tissue constructs for transplantation and drug analysis responses. The recent product launches with better mimic conditions in the human body are likely to support market growth. For instance, in June 2020, FaCellitate announced the launch of BIOFLOAT for improved 3D cell culture. The product is convenient to use, which creates optimal conditions for multicellular spheroids.

Moreover, pharmaceutical companies, academic institutions, and research institutes are partnering to advance 3D cell culture technology. Such efforts accelerate technology advancement, knowledge sharing, and standardization of protocols, resulting in the larger adoption of 3D cell culture techniques. In addition, the supportive government legislation, and funding support from public and private organizations have accelerated the R&D activities in the market. For instance, in March 2023, ZEISS Ventures invested in InSphero to promote 3D cell culture research. In addition, in December 2021 Inventia Life Science accelerated growth with USD 23.1 million series B funding and launched a 3D cell culture platform in the U.S. market.

3D Cell Culture Market Report Scope

Furthermore, robust demand for in-vitro testing models from a range of end-users, and several organic and inorganic initiatives undertaken by market players is anticipated to facilitate market expansion in coming years. For instance, in February 2020, zPREDICTA, Inc. announced a strategic collaboration with LabCorp. This collaboration aims to advance the use of 3D cell cultures in drug research and development. Similarly, in October 2020 Merck collaborated with D1 Med to accelerate manufacturing of D1Med’s 3-dimensional cells culture technology applications adopted in the drug development process.

The key players in the 3D cell culture industry are undertaking various strategic initiatives to maintain their market presence. In addition, various strategic initiatives help market players to bolster their business avenues. For instance, in January 2023, CD BioSciences launched scaffold-based technology to help scientists in achieving organotypic co-culture and simulating layered tissue structures.

List of Key Players in the 3D Cell Culture Market

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• PromoCell GmbH
• Lonza
• Corning Incorporated
• Avantor, Inc. 
• Tecan Trading AG
• REPROCELL Inc.
• CN Bio Innovations Ltd
• Lena Biosciences